WO1999062945A3 - Peptide antigens for detection of hiv, hcv and other microbial infections - Google Patents

Peptide antigens for detection of hiv, hcv and other microbial infections Download PDF

Info

Publication number
WO1999062945A3
WO1999062945A3 PCT/US1999/012446 US9912446W WO9962945A3 WO 1999062945 A3 WO1999062945 A3 WO 1999062945A3 US 9912446 W US9912446 W US 9912446W WO 9962945 A3 WO9962945 A3 WO 9962945A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
peptide
naturally occurring
disease
advantageous
Prior art date
Application number
PCT/US1999/012446
Other languages
French (fr)
Other versions
WO1999062945A2 (en
WO1999062945A9 (en
Inventor
Mohammed Afzal Chowdhury
David Bernstein
Marvin A Motsenbocker
Original Assignee
Peptide Solutions Inc
Mohammed Afzal Chowdhury
David Bernstein
Marvin A Motsenbocker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/001726 external-priority patent/WO1999038887A1/en
Application filed by Peptide Solutions Inc, Mohammed Afzal Chowdhury, David Bernstein, Marvin A Motsenbocker filed Critical Peptide Solutions Inc
Priority to AU45463/99A priority Critical patent/AU4546399A/en
Publication of WO1999062945A2 publication Critical patent/WO1999062945A2/en
Publication of WO1999062945A9 publication Critical patent/WO1999062945A9/en
Publication of WO1999062945A3 publication Critical patent/WO1999062945A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

Improved peptide antigens for diagnostic testing and therapy of disease are provided which differ from naturally occurring peptide sequences. These peptides immunologically cross-react with a wide variety of mutated forms of antigens and are particularly useful for testing and treatment of retroviral disease such as HIV infection, where rapid mutation of the disease vector is a concern. The peptides are from about 25 to about 100 amino acid residues long and, in addition to advantageous reactivity, also may possess one or more other advantageous characteristics such as improved water solubility or improved immunological reactivity as compared to naturally occurring strains such as ANT70 and MVP5180. Advantageous alterations include substitution of one or more hydrophobic residues with hydrophilic residues, removal of a basic amino acid positive charge to decrease non-specific binding and increase in peptide secondary structure by adding one or more amino acids to form or extend an alpha helix within the peptide. The claimed invention is exemplified by substitution of leucine by glutamine and by arginine in HIV envelope protein peptides. Peptides that have been modified according to principles of the claimed invention differ greatly from the naturally occurring forms and are not identified as belonging to any particular viral Group or strain.
PCT/US1999/012446 1998-06-05 1999-06-04 Peptide antigens for detection of hiv, hcv and other microbial infections WO1999062945A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU45463/99A AU4546399A (en) 1998-06-05 1999-06-04 Universal peptides

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US8822998P 1998-06-05 1998-06-05
US60/088,229 1998-06-05
US9870598P 1998-09-01 1998-09-01
US60/098,705 1998-09-01
US10042298P 1998-09-15 1998-09-15
US60/100,422 1998-09-15
USPCT/US99/01726 1999-01-28
PCT/US1999/001726 WO1999038887A1 (en) 1998-01-28 1999-01-28 Divergent hiv-1 peptides

Publications (3)

Publication Number Publication Date
WO1999062945A2 WO1999062945A2 (en) 1999-12-09
WO1999062945A9 WO1999062945A9 (en) 2000-05-04
WO1999062945A3 true WO1999062945A3 (en) 2000-06-29

Family

ID=27492207

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/012446 WO1999062945A2 (en) 1998-06-05 1999-06-04 Peptide antigens for detection of hiv, hcv and other microbial infections

Country Status (1)

Country Link
WO (1) WO1999062945A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1100564C (en) * 2001-08-29 2003-02-05 周根发 Medicine for treating HIV infection, its composition and its use

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993006488A1 (en) * 1991-09-16 1993-04-01 Genelabs Technologies, Inc. Peptide based hepatitis c virus immunoassays
EP0591914A2 (en) * 1992-10-06 1994-04-13 BEHRINGWERKE Aktiengesellschaft Retrovirus of the HIV-group and its application
DE4405810A1 (en) * 1994-02-23 1995-08-24 Behringwerke Ag Peptides derived from a retrovirus from the HIV group and their use
WO1996012809A2 (en) * 1994-10-20 1996-05-02 Institut Pasteur Nucleotide sequences of hiv-1 type (or subtype) o retrovirus antigens
WO1996027013A1 (en) * 1995-02-27 1996-09-06 Institut National De La Sante Et De La Recherche Medicale-Inserm Group o hiv-1, fragments of such viruses, and uses thereof
WO1998045318A1 (en) * 1997-04-07 1998-10-15 Syva Company Activated peptides and conjugates
WO1999004011A2 (en) * 1997-07-18 1999-01-28 Innogenetics N.V. Hiv-1 group o antigens and uses thereof
WO1999045395A1 (en) * 1998-03-04 1999-09-10 Universal Healthwatch, Inc. Rapid confirmatory test for microbial infections

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993006488A1 (en) * 1991-09-16 1993-04-01 Genelabs Technologies, Inc. Peptide based hepatitis c virus immunoassays
EP0591914A2 (en) * 1992-10-06 1994-04-13 BEHRINGWERKE Aktiengesellschaft Retrovirus of the HIV-group and its application
DE4405810A1 (en) * 1994-02-23 1995-08-24 Behringwerke Ag Peptides derived from a retrovirus from the HIV group and their use
WO1996012809A2 (en) * 1994-10-20 1996-05-02 Institut Pasteur Nucleotide sequences of hiv-1 type (or subtype) o retrovirus antigens
WO1996027013A1 (en) * 1995-02-27 1996-09-06 Institut National De La Sante Et De La Recherche Medicale-Inserm Group o hiv-1, fragments of such viruses, and uses thereof
WO1998045318A1 (en) * 1997-04-07 1998-10-15 Syva Company Activated peptides and conjugates
WO1999004011A2 (en) * 1997-07-18 1999-01-28 Innogenetics N.V. Hiv-1 group o antigens and uses thereof
WO1999045395A1 (en) * 1998-03-04 1999-09-10 Universal Healthwatch, Inc. Rapid confirmatory test for microbial infections

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCHABLE ET AL: "Sensitivity of United States HIV antibody tests for detection of HIV-1 group O infections", SYNTHESIS, vol. 344, no. 344, 12 November 1994 (1994-11-12), pages 1333/1334, XP002098165 *

Also Published As

Publication number Publication date
WO1999062945A2 (en) 1999-12-09
WO1999062945A9 (en) 2000-05-04

Similar Documents

Publication Publication Date Title
JP2752329B2 (en) Method for producing envelope antigen of virus of lymphadenopathy and acquired immunodeficiency syndrome
US7445903B2 (en) Fibrin citrulline derivatives and their use for diagnosing or treating rheumatoid arthritis
KR950032278A (en) Peptides Derived from Retroviruses of the Human Immunodeficiency Virus Group and Uses thereof
EP0328403A3 (en) Synthetic peptides related to the hiv-gp120-env-protein, and their use
RU2006105498A (en) POLYEPEPTIDES FOR THE INDUCTION OF A PROTECTIVE IMMUNE RESPONSE AGAINST STAPHYLOCOCCUS AUREUS
AU5376201A (en) Methods and compositions for impairing multiplication of hiv-1
CA2380833A1 (en) Proteins derived from white spot syndrome virus and uses thereof
CA2391356A1 (en) Peptides designed for the diagnosis and treatment of rheumatoid arthritis
US4755380A (en) Peptide from amyloid A and antiserum therefor
WO1999062945A3 (en) Peptide antigens for detection of hiv, hcv and other microbial infections
AU5776799A (en) Modified hcv peptide vaccines
IL156799A (en) Peptides having affinity for the gp120 viral protein and use thereof
WO2003022879B1 (en) Peptides mimicking a cryptic epitope of gp41 hiv-1 and antibodies directed against them
WO2001029177A3 (en) Hiv-1 subtype d peptides
RU2184742C2 (en) Synthetic peptides using in biological tests for detection infections caused by viruses hiv-1 of group 0
CORDIALI et al. Convergent evolution in the homology between HIV gp160 and HLA class II molecules
CA2057612A1 (en) Selected peptides of the group-specific antigen (gag) of human immunodeficiency virus (hiv), the preparation and use thereof
AU6393990A (en) Hiv related peptides
WO1998037089A3 (en) Matrix derived anti-hiv peptides and transdominant proteins
WO1996027012A1 (en) Specific hiv-1 group o antigens
WO2000001719A3 (en) Peptides from varicella-zoster and other viruses for hiv-2 diagnosis and therapy
Crescenzi et al. Synthetic peptides in diagnosis of plum pox potyvirus
US6555091B1 (en) Polypeptide capable of reacting with antibodies of patients suffering from multiple sclerosis and uses
Furuishi et al. A Novel Monoclonal Antibody toN-Myristoyl Glycine Moiety Found a NewN-Myristoylated HIV-1 p28gagProtein in HIV-1-Infected Cells
CA2290217A1 (en) Peptides for the detection of hiv-1 group o

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/6-6/6, DRAWINGS, REPLACED BY NEW PAGES 1/7-7/7; PAGES 60-75, SEQUENCE LISTING, RENUMBERED AS PAGES 1-16; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase